Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 19 studies | 34% ± 14% | |
| astrocyte | 16 studies | 37% ± 17% | |
| ciliated cell | 14 studies | 34% ± 14% | |
| oligodendrocyte | 14 studies | 38% ± 15% | |
| macrophage | 13 studies | 28% ± 11% | |
| oligodendrocyte precursor cell | 12 studies | 43% ± 16% | |
| GABAergic neuron | 11 studies | 46% ± 23% | |
| glutamatergic neuron | 11 studies | 54% ± 24% | |
| microglial cell | 11 studies | 34% ± 12% | |
| mast cell | 10 studies | 34% ± 8% | |
| B cell | 9 studies | 23% ± 6% | |
| epithelial cell | 9 studies | 41% ± 20% | |
| adipocyte | 9 studies | 29% ± 7% | |
| neuron | 7 studies | 46% ± 21% | |
| basal cell | 7 studies | 34% ± 15% | |
| retinal cone cell | 7 studies | 43% ± 14% | |
| myeloid cell | 7 studies | 30% ± 10% | |
| endothelial cell of lymphatic vessel | 7 studies | 32% ± 9% | |
| natural killer cell | 7 studies | 20% ± 5% | |
| fibroblast | 7 studies | 25% ± 9% | |
| interneuron | 6 studies | 58% ± 19% | |
| retinal ganglion cell | 6 studies | 32% ± 6% | |
| club cell | 6 studies | 31% ± 10% | |
| amacrine cell | 6 studies | 29% ± 8% | |
| retina horizontal cell | 6 studies | 34% ± 8% | |
| dendritic cell | 6 studies | 25% ± 3% | |
| T cell | 6 studies | 21% ± 4% | |
| type I pneumocyte | 6 studies | 24% ± 5% | |
| type II pneumocyte | 6 studies | 37% ± 10% | |
| goblet cell | 6 studies | 28% ± 17% | |
| brush cell | 5 studies | 37% ± 12% | |
| cardiac muscle cell | 5 studies | 40% ± 12% | |
| respiratory goblet cell | 5 studies | 36% ± 12% | |
| monocyte | 5 studies | 26% ± 6% | |
| retinal bipolar neuron | 4 studies | 33% ± 7% | |
| granule cell | 4 studies | 39% ± 17% | |
| lymphocyte | 4 studies | 33% ± 7% | |
| ON-bipolar cell | 4 studies | 31% ± 10% | |
| abnormal cell | 4 studies | 28% ± 16% | |
| erythrocyte | 4 studies | 49% ± 19% | |
| pericyte | 4 studies | 22% ± 3% | |
| smooth muscle cell | 4 studies | 20% ± 4% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 21% ± 7% | |
| naive thymus-derived CD4-positive, alpha-beta T cell | 3 studies | 18% ± 4% | |
| capillary endothelial cell | 3 studies | 18% ± 1% | |
| GABAergic interneuron | 3 studies | 44% ± 6% | |
| glial cell | 3 studies | 27% ± 4% | |
| plasma cell | 3 studies | 31% ± 6% | |
| squamous epithelial cell | 3 studies | 40% ± 18% | |
| CD4-positive, alpha-beta T cell | 3 studies | 20% ± 3% | |
| mononuclear phagocyte | 3 studies | 26% ± 8% | |
| GABAergic amacrine cell | 3 studies | 39% ± 8% | |
| OFF-bipolar cell | 3 studies | 30% ± 8% | |
| glycinergic amacrine cell | 3 studies | 32% ± 2% | |
| retinal rod cell | 3 studies | 23% ± 5% | |
| rod bipolar cell | 3 studies | 45% ± 11% | |
| retinal pigment epithelial cell | 3 studies | 38% ± 19% | |
| ependymal cell | 3 studies | 49% ± 15% | |
| megakaryocyte-erythroid progenitor cell | 3 studies | 50% ± 16% | |
| enteroendocrine cell | 3 studies | 31% ± 9% | |
| alveolar macrophage | 3 studies | 33% ± 6% | |
| erythroblast | 3 studies | 29% ± 14% | |
| mucus secreting cell | 3 studies | 32% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| adrenal gland | 100% | 7746.71 | 258 / 258 | 100% | 41.83 | 230 / 230 |
| esophagus | 100% | 4483.74 | 1445 / 1445 | 100% | 47.22 | 183 / 183 |
| prostate | 100% | 3109.13 | 245 / 245 | 100% | 23.82 | 501 / 502 |
| intestine | 100% | 3603.35 | 966 / 966 | 100% | 41.97 | 525 / 527 |
| bladder | 100% | 3634.62 | 21 / 21 | 100% | 37.77 | 502 / 504 |
| brain | 100% | 3889.77 | 2639 / 2642 | 100% | 31.00 | 703 / 705 |
| breast | 100% | 3771.78 | 459 / 459 | 100% | 42.02 | 1113 / 1118 |
| stomach | 100% | 3590.01 | 359 / 359 | 99% | 46.13 | 284 / 286 |
| ovary | 99% | 2816.68 | 179 / 180 | 100% | 45.56 | 428 / 430 |
| lung | 99% | 2886.22 | 575 / 578 | 99% | 32.37 | 1148 / 1155 |
| skin | 100% | 5859.57 | 1809 / 1809 | 99% | 45.15 | 466 / 472 |
| thymus | 100% | 2955.09 | 653 / 653 | 98% | 22.43 | 594 / 605 |
| uterus | 100% | 2229.46 | 170 / 170 | 98% | 25.25 | 450 / 459 |
| kidney | 100% | 2797.29 | 89 / 89 | 97% | 21.70 | 870 / 901 |
| pancreas | 97% | 1559.92 | 319 / 328 | 99% | 29.49 | 176 / 178 |
| liver | 97% | 1380.30 | 219 / 226 | 56% | 8.17 | 226 / 406 |
| adipose | 100% | 3167.87 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 18.63 | 29 / 29 |
| spleen | 100% | 4521.42 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 21.93 | 1 / 1 |
| blood vessel | 100% | 2490.05 | 1332 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 99% | 2264.99 | 794 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 98% | 20.21 | 44 / 45 |
| heart | 94% | 1894.91 | 811 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 91% | 19.55 | 73 / 80 |
| peripheral blood | 61% | 1799.01 | 568 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006325 | Biological process | chromatin organization |
| GO_1902952 | Biological process | positive regulation of dendritic spine maintenance |
| GO_1902897 | Biological process | regulation of postsynaptic density protein 95 clustering |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0032968 | Biological process | positive regulation of transcription elongation by RNA polymerase II |
| GO_0098815 | Biological process | modulation of excitatory postsynaptic potential |
| GO_0000724 | Biological process | double-strand break repair via homologous recombination |
| GO_0051491 | Biological process | positive regulation of filopodium assembly |
| GO_0060999 | Biological process | positive regulation of dendritic spine development |
| GO_0071168 | Biological process | protein localization to chromatin |
| GO_0030336 | Biological process | negative regulation of cell migration |
| GO_0007399 | Biological process | nervous system development |
| GO_0005730 | Cellular component | nucleolus |
| GO_0043197 | Cellular component | dendritic spine |
| GO_0043198 | Cellular component | dendritic shaft |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0090734 | Cellular component | site of DNA damage |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0000785 | Cellular component | chromatin |
| GO_0005634 | Cellular component | nucleus |
| GO_0035064 | Molecular function | methylated histone binding |
| GO_0140297 | Molecular function | DNA-binding transcription factor binding |
| GO_0019904 | Molecular function | protein domain specific binding |
| GO_0070577 | Molecular function | lysine-acetylated histone binding |
| GO_0003714 | Molecular function | transcription corepressor activity |
| GO_0008270 | Molecular function | zinc ion binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | ZMYND8 |
| Protein name | MYND-type zinc finger-containing chromatin reader ZMYND8 (Cutaneous T-cell lymphoma-associated antigen se14-3) (CTCL-associated antigen se14-3) (Protein kinase C-binding protein 1) (Rack7) (Transcription coregulator ZMYND8) (Zinc finger MYND domain-containing protein 8) Zinc finger MYND-type containing 8 ZMYND8 protein |
| Synonyms | PRKCBP1 KIAA1125 RACK7 |
| Description | FUNCTION: Chromatin reader that recognizes dual histone modifications such as histone H3.1 dimethylated at 'Lys-36' and histone H4 acetylated at 'Lys-16' (H3.1K36me2-H4K16ac) and histone H3 methylated at 'Lys-4' and histone H4 acetylated at 'Lys-14' (H3K4me1-H3K14ac) . May act as a transcriptional corepressor for KDM5D by recognizing the dual histone signature H3K4me1-H3K14ac . May also act as a transcriptional corepressor for KDM5C and EZH2 . Recognizes acetylated histone H4 and recruits the NuRD chromatin remodeling complex to damaged chromatin for transcriptional repression and double-strand break repair by homologous recombination . Also activates transcription elongation by RNA polymerase II through recruiting the P-TEFb complex to target promoters . Localizes to H3.1K36me2-H4K16ac marks at all-trans-retinoic acid (ATRA)-responsive genes and positively regulates their expression . Promotes neuronal differentiation by associating with regulatory regions within the MAPT gene, to enhance transcription of a protein-coding MAPT isoform and suppress the non-coding MAPT213 isoform . Suppresses breast cancer, and prostate cancer cell invasion and metastasis . . |
| Accessions | ENST00000352431.6 [Q9ULU4-12] ENST00000617418.4 ENST00000311275.11 [Q9ULU4-1] ENST00000355972.8 [Q9ULU4-11] A0A087WV57 ENST00000262975.8 [Q9ULU4-9] ENST00000536340.5 [Q9ULU4-19] Q5TH12 Q9ULU4 ENST00000471951.7 [Q9ULU4-7] ENST00000372023.7 [Q9ULU4-23] ENST00000360911.7 [Q9ULU4-14] ENST00000396281.8 [Q9ULU4-20] ENST00000461685.5 [Q9ULU4-13] ENST00000441977.1 ENST00000458360.6 [Q9ULU4-17] Q5TH07 ENST00000446994.6 [Q9ULU4-11] ENST00000611941.4 ENST00000467200.6 ENST00000435836.5 A6H8Y8 ENST00000619049.4 A0A087WVZ6 Q569J9 ENST00000446894.5 ENST00000540497.5 [Q9ULU4-18] A0A087WYS3 Q5TH08 H7C4X9 |